Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial

Authors :: Dormandy, John A.
Charbonnel, Bernard
Eckland, David J.A.
Erdmann, Erland
Benedetti, Massimo Massi
Moules, Ian K.
Skene, Allan M.
Tan, Meng H.
Lefebvre, Pierre J.
Murray, Gordon D.
Standl, Eberhard
Wilcox, Robert G.
Wilhelmsen, Lars
Betteridge, John
Birkeland, Kare
Golay, Alain
Heine, Robert J.
Koranyi, Laszlo
Laakso, Markku
Mokan, Marian
Norkus, Antanas
Pirags, Valdis
Podar, Toomas
Scheen, Andre
Scherbaum, Werner
Schernthaner, Guntram
Schmitz, Ole
Skrha, Jan
Smith, Ulf
Taton, Jan
Source :: The Lancet. Oct 8, 2005, Vol. 366 Issue 9493, p1279, 11 p.
Publication Year :: 2005

Subjects :: Type 2 diabetes -- Complications and side effects
Type 2 diabetes -- Care and treatment
Type 2 diabetes -- Physiological aspects
Type 2 diabetes -- Drug therapy
Cardiovascular diseases -- Risk factors
Cardiovascular diseases -- Causes of
Cardiovascular diseases -- Prevention

Tools